Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Prasinezumab in Early Parkinson's Disease
CTR20260021Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of prasinezumab in Parkinson's disease (PD), sponsored by Roche. Started Mar 2026; status: active.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20260021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260021.